Related Experiment Videos
Summary
Dihydroergotamine improves lower limb phlebography by enhancing contrast and visualizing deep veins. This pharmacologic agent aids in diagnosing venous diseases when standard imaging is insufficient.
Area of Science:
- Vascular Medicine
- Diagnostic Imaging
- Pharmacology
Background:
- Phlebography of the lower limb deep venous system can suffer from insufficient contrast or missed veins, varying with venous disease type.
- This limitation impacts accurate diagnosis and treatment planning for venous disorders.
Purpose of the Study:
- To investigate the effect of dihydroergotamine on improving the diagnostic quality of lower limb phlebography.
- To determine if dihydroergotamine can enhance contrast and visualize previously un-imaged deep veins.
Main Methods:
- A study was conducted to observe the effects of dihydroergotamine on blood flow shifts from superficial to deep venous systems.
- Phlebography was performed before and after intravenous administration of 0.5-1.0 mg dihydroergotamine in patients with suspected venous disease.
- A control group without pharmacologic intervention was included for comparison.
Main Results:
- Dihydroergotamine administration resulted in a significant contrast enhancement in 85.7% of cases.
- Previously un-imaged deep veins were successfully visualized in 75% of patients after dihydroergotamine administration.
- Control studies without dihydroergotamine did not yield comparable improvements in imaging quality.
Conclusions:
- Intravenous dihydroergotamine administration can significantly improve the diagnostic value of phlebography in challenging cases.
- This pharmacologic approach aids in overcoming contrast limitations and visualizing critical deep venous structures.
- Dihydroergotamine is a valuable adjunct for phlebography in diagnosing lower limb venous diseases when initial imaging is suboptimal.